Lee Schwartzberg Selected Research

Vomiting

1/2021	Avoidable Acute Care Use Associated with Nausea and Vomiting Among Patients Receiving Highly Emetogenic Chemotherapy or Oxaliplatin.
1/2021	Efficacy of intravenous NEPA, a fixed NK1/5-HT3 receptor antagonist combination, for the prevention of chemotherapy-induced nausea and vomiting (CINV) during cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy: A review of phase 3 studies.
1/2020	What the HEC? Clinician Adherence to Evidence-Based Antiemetic Prophylaxis for Highly Emetogenic Chemotherapy.
1/2020	Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy.
4/2019	Timing flexibility of oral NEPA, netupitant-palonosetron combination, administration for the prevention of chemotherapy-induced nausea and vomiting (CINV).
4/2019	Preventing chemotherapy-induced nausea and vomiting with netupitant/palonosetron, the first fixed combination antiemetic: current and future perspective.
1/2019	Fixed combination of oral NEPA (netupitant-palonosetron) for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double-blind phase III studies.
1/2018	Getting it right the first time: recent progress in optimizing antiemetic usage.
1/2018	Recent advances in antiemetics: new formulations of 5HT3-receptor antagonists.
1/2018	Searching for perfection: further progress in management of chemotherapy-induced nausea and vomiting-CME information.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lee Schwartzberg Research Topics

Disease

39	Neoplasms (Cancer) 01/2022 - 04/2003
30	Nausea 01/2021 - 02/2006
28	Vomiting 01/2021 - 02/2006
27	Breast Neoplasms (Breast Cancer) 01/2022 - 12/2005
9	Neutropenia 01/2022 - 05/2004
7	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2019 - 10/2006
6	Colorectal Neoplasms (Colorectal Cancer) 01/2017 - 03/2004
4	Disease Progression 10/2021 - 12/2013
4	Anemia 10/2010 - 11/2003
3	Triple Negative Breast Neoplasms 10/2021 - 12/2014
3	Fatigue 12/2020 - 12/2013
3	Pain (Aches) 09/2018 - 04/2003
3	Febrile Neutropenia 09/2018 - 07/2014
2	Lung Neoplasms (Lung Cancer) 01/2021 - 01/2017
2	Hypersensitivity (Allergy) 01/2021 - 01/2020
2	Exanthema (Rash) 12/2013 - 10/2006
1	COVID-19 11/2021
1	Pathologic Complete Response 10/2021
1	Injection Site Reaction 01/2021
1	Uterine Neoplasms (Uterine Cancer) 01/2021
1	Neoplasm Metastasis (Metastasis) 01/2021
1	Residual Neoplasm 01/2020
1	Anaphylaxis (Anaphylactic Shock) 01/2020
1	Hematologic Neoplasms (Hematological Malignancy) 11/2019
1	Carcinogenesis 11/2019

Drug/Important Bio-Agent (IBA)

15	AntiemeticsIBA 01/2021 - 02/2006
13	Hormones (Hormone)IBA 01/2022 - 07/2012
11	AnthracyclinesIBA 01/2021 - 06/2008
10	Palonosetron (Aloxi)FDA Link 04/2019 - 02/2006
8	human ERBB2 proteinIBA 01/2022 - 01/2013
7	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2021 - 07/2015
7	Pharmaceutical PreparationsIBA 01/2018 - 12/2005
6	Estrogen ReceptorsIBA 10/2021 - 05/2018
6	taxaneIBA 01/2015 - 10/2006
5	Dexamethasone (Maxidex)FDA LinkGeneric 01/2021 - 01/2017
5	Cisplatin (Platino)FDA LinkGeneric 01/2021 - 11/2009
5	netupitantIBA 04/2019 - 01/2017
4	ErbB Receptors (EGF Receptor)IBA 10/2021 - 12/2013
4	Trastuzumab (Herceptin)FDA Link 01/2020 - 01/2014
4	eribulin FDA Link 06/2019 - 07/2014
4	PlatinumIBA 01/2019 - 10/2006
4	rolapitantIBA 01/2017 - 04/2016
4	Pemetrexed (MTA)FDA Link 12/2013 - 10/2009
4	Darbepoetin alfa (Aranesp)FDA Link 10/2010 - 11/2003
3	beta-Aminoethyl Isothiourea (AET)IBA 10/2021 - 12/2019
3	5-HT3 Serotonin Receptors (5 HT3 Receptor)IBA 01/2021 - 08/2011
3	Biomarkers (Surrogate Marker)IBA 04/2020 - 05/2016
3	Neurokinin-1 Receptor AntagonistsIBA 01/2017 - 02/2006
3	Ondansetron (Zofran)FDA LinkGeneric 01/2017 - 02/2014
3	Granisetron (Kytril)FDA LinkGeneric 01/2017 - 02/2014
3	Aprepitant (Emend)FDA Link 01/2017 - 02/2006
3	Monoclonal AntibodiesIBA 09/2015 - 04/2009
3	Carboplatin (JM8)FDA LinkGeneric 07/2015 - 11/2009
3	Gemcitabine FDA Link 12/2014 - 10/2009
3	Capecitabine (Xeloda)FDA Link 01/2014 - 06/2008
3	Bevacizumab (Avastin)FDA Link 12/2013 - 07/2008
2	RNA (Ribonucleic Acid)IBA 11/2021 - 03/2020
2	Progesterone Receptors (Progesterone Receptor)IBA 10/2021 - 02/2020
2	palbociclibIBA 10/2021 - 02/2020
2	Letrozole (Femara)FDA LinkGeneric 10/2021 - 02/2020
2	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2021 - 07/2008
2	Lapatinib (GW572016)FDA Link 01/2020 - 01/2014
2	Circulating Tumor DNAIBA 01/2020 - 05/2016
2	Filgrastim (Neupogen)FDA Link 09/2018 - 05/2004
2	pegfilgrastim (Neulasta)FDA Link 09/2018 - 05/2004
2	Colony-Stimulating Factors (Colony Stimulating Factor)IBA 09/2018 - 05/2004
2	DNA (Deoxyribonucleic Acid)IBA 02/2018 - 05/2016
2	Serotonin (5 Hydroxytryptamine)IBA 01/2018 - 01/2017
2	Olanzapine (Zyprexa)FDA Link 01/2018 - 01/2017
2	EmeticsIBA 01/2017 - 02/2014
2	Cetuximab (Erbitux)FDA Link 09/2015 - 12/2013
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 12/2014 - 07/2014
2	Paclitaxel (Taxol)FDA LinkGeneric 01/2013 - 11/2009
2	Hemoglobins (Hemoglobin)IBA 10/2010 - 02/2004
2	Fluorouracil (Carac)FDA LinkGeneric 04/2009 - 03/2004
2	Epoetin Alfa (Epogen)FDA Link 12/2005 - 11/2003
1	Peptide Hydrolases (Proteases)FDA Link 11/2021
1	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 11/2021
1	Biological ProductsIBA 11/2021
1	enzalutamideIBA 12/2020
1	exemestane (Aromasin)FDA Link 12/2020
1	Androgen Receptors (Androgen Receptor)IBA 12/2020
1	Phenobarbital (Luminal)FDA Link 03/2020
1	Tyrosine Kinase InhibitorsIBA 01/2020
1	neratinibIBA 01/2020
1	pertuzumabIBA 01/2020
1	fosaprepitant FDA Link 01/2020
1	Immunoconjugates (Immunoconjugate)IBA 01/2020
1	NVP-BKM120IBA 11/2019
1	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 11/2019
1	niraparibIBA 08/2019
1	Poly Adenosine Diphosphate RiboseIBA 08/2019
1	pembrolizumabIBA 08/2019

Therapy/Procedure

48	Drug Therapy (Chemotherapy) 01/2022 - 11/2003
41	Therapeutics 01/2022 - 10/2006
6	Adjuvant Chemotherapy 01/2022 - 07/2014
4	Drug Tapering 12/2014 - 06/2008
3	Precision Medicine 01/2021 - 01/2020
1	Hysterectomy 01/2021
1	Simple Mastectomy 02/2020